Chlorprothixene is a typical antipsychotic drug used to treat schizophrenia, severe anxiety, and agitation, as well as to manage insomnia in certain psychiatric conditions. As a thioxanthene derivative, it belongs to the class of dopamine D2 receptor antagonists, which work by modulating neurotransmitter activity in the brain to reduce psychotic symptoms and stabilize mood. It is one of the older antipsychotic agents that remains in use for patients who require sedative or neuroleptic effects. It was developed in the 1960s and has been used clinically for decades in Europe and other regions.
BRAND NAMES
Truxal – widely used in Europe
Taractan – available in some countries
Clozan – less common
Chlorprothixene Hydrochloride – generic formulations
MECHANISM OF ACTION
Chlorprothixene is a typical antipsychotic of the thioxanthene class. Its primary mechanism of action is dopamine D2 receptor antagonism in the brain, particularly in the mesolimbic and mesocortical pathways. By blocking D2 receptors, it reduces excessive dopaminergic activity, which is associated with psychotic symptoms such as hallucinations, delusions, and agitation.
PHARMACOKINETICS
Absorption
Chlorprothixene is well absorbed after oral administration, but it undergoes extensive first-pass metabolism in the liver, which reduces the fraction of the active drug reaching systemic circulation. Peak plasma concentrations are usually reached 1–3 hours after oral dosing. Bioavailability can vary depending on the formulation (e.g., tablets vs. oral solution) and individual metabolic differences.
Distribution
Chlorprothixene is extensively distributed throughout the body, with a volume of distribution of 10–15 L/kg. It is highly protein-bound (90–95%), primarily to albumin, and accumulates in tissues including the brain, liver, lungs, and kidneys, which supports its central antipsychotic effects. Its ability to cross the blood-brain barrier is key to its therapeutic action.
Metabolism
Chlorprothixene is extensively metabolized in the liver, primarily by cytochrome P450 enzymes (including CYP2D6). It undergoes N-demethylation, sulfoxidation, and hydroxylation, producing several active and inactive metabolites. Hepatic metabolism is a major factor in its first-pass effect, influencing oral bioavailability and inter-individual variability in drug levels.
Excretion
Chlorprothixene and its metabolites are primarily excreted via the urine, with a smaller portion eliminated in the feces. The drug has an elimination half-life of approximately 15–30 hours, which supports once- or twice-daily dosing. Renal and hepatic function can influence clearance, so dose adjustments may be needed in patients with liver or kidney impairment.
PHARMACODYNAMICS
Chlorprothixene is a typical antipsychotic of the thioxanthene class. Its therapeutic effects are primarily due to dopamine D2 receptor antagonism in the mesolimbic and mesocortical pathways, which reduces psychotic symptoms such as hallucinations, delusions, and agitation.
ADMINISTRATION
Administration is the process of managing and organizing the activities of an organization, institution, or government to achieve its goals effectively. It involves planning, decision-making, coordination, and supervision of resources and people. Good administration ensures smooth functioning, proper use of resources, and timely completion of tasks in areas like education, business, and public services.
DOSAGE AND STRENGTH
Adults (oral): Typically 25–200 mg per day, divided into 2–3 doses.
Elderly or debilitated patients: Start at lower doses, 10–25 mg 2–3 times daily, to reduce sedation and hypotension risk.
Intramuscular injection: Used for acute agitation or severe psychosis; doses usually 25–50 mg, repeated as necessary under medical supervision.
Titration: Dose adjustments should be gradual to minimize side effects.
DRUG INTERACTIONS
CNS depressants (e.g., benzodiazepines, alcohol, opioids) – can increase sedation, respiratory depression, and hypotension.
Other antipsychotics or antiarrhythmics – may prolong QT interval, increasing risk of cardiac arrhythmias.
Antihypertensives – additive blood pressure-lowering effects, causing orthostatic hypotension.
CYP2D6 substrates, inhibitors, or inducers – drugs affecting CYP2D6 (e.g., fluoxetine, paroxetine) can alter chlorprothixene plasma levels, either increasing toxicity or reducing efficacy.
FOOD INTERACTIONS
Chlorprothixene can be taken with or after meals to minimize stomach irritation. Food may slightly delay absorption but does not reduce its effectiveness. Alcohol should be avoided, as it can increase sedation and dizziness, while caffeine or stimulants may counteract its calming effects
CONTRAINDICATIONS
Hypersensitivity to chlorprothixene or other thioxanthene derivatives
Severe central nervous system depression or comatose states
Bone marrow suppression or severe blood disorders
Severe cardiovascular disease, including recent myocardial infarction, severe hypotension, or arrhythmias
Severe liver or kidney impairment (may impair metabolism and excretion)
Parkinson’s disease (dopamine antagonism can worsen symptoms)
Children under certain ages, depending on formulation and local guidelines
SIDE EFFECTS
Sedation and drowsiness
Dizziness and hypotension
Dry mouth
Constipation
Blurred vision
Extrapyramidal symptoms (tremor, rigidity, akathisia)
Tardive dyskinesia
Weight gain
Hyperprolactinemia
Cardiac arrhythmias
Rare: agranulocytosis, severe allergic reactions
OVER DOSE
Chlorprothixene overdose is serious and can cause drowsiness, confusion, seizures, or irregular heartbeat. Call emergency services immediately and seek hospital care.
TOXICITY
Chlorprothixene toxicity occurs when the drug reaches harmful levels in the body. It can cause drowsiness, confusion, low blood pressure, irregular heartbeat, seizures, and coma. Toxicity requires immediate medical attention with monitoring of heart, breathing, and supportive care in a hospital.
